RE:Comparing market caps is helpfulWould tend to agree with you here, but I also believe we should factor in both top line sales revenues and bottom line profits when we do this exercise.
Did I read somewhere that Auxley was expected to have total sales of only around $25M for 2018 FY with negative earnings before moving up to just north of $100M in total sales for 2019FY. Actually, not sure if I am a year ahead of myself with these numbers here.
Aurora is believed to have something like $75M total sales revenue for 2018 FY and then something like low $400M and low $900M for the 2 years after that. Canopy is supposed to have about $80M for this coming year and then I thought ??? something like the mid $300M and mid $900M range in the 2 years after that.
Of course, it's rather hard to do a fair comparison between these companies since they all have different fiscal year reporting time periods.
MPetersen wrote: If you look at market capitalization and price, there are very few bargains that are worth it like Auxly. And I would say that few of these companies are actually worth their market cap like Auxly.
Canopy: $12.9 billion
Aurora: $8.2 billion
Tilray: $4 billion
Aphria: $3.3 billion
Cronos: $2.3 billion
Hydropothecary: $1 billion
CannTrust: $1 billion
Organigram: $739.9 million
Emerald: $645 million
Auxly: $620 million
Namaste: $514 million
Supreme: $436 million
Newstrike: $421 million
Hiku: $376 million
Vivo (ABCann): $291.8 million
FSD Pharma: $224 million
Emblem: $185 million